Testing the Addition of Chemotherapy Drug, Cisplatin, to Usual Radiation Therapy for Patients with Head and Neck Cancer
Greg Durm, MD
Primary Investigator
Brief description of study
The purpose of this study is to compare two treatment approaches that are currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone. A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.
Detailed description of study
Participants will be assigned to receive either radiation therapy, or radiation therapy along with cisplatin. Both groups will receive treatment for 6 weeks with the doctor following their condition for 10 years after treatment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Head and Neck Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Individuals at least 18 years of age with squamous cell carcinoma of the head/neck, that has been surgically removed.
Individuals with recurrent disease or multiple primaries will not be eligible.
Women who are pregnant or breastfeeding will not be eligible.
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
